Celldex Therapeutics, Inc. (NASDAQ: CLDX) is a Healthcare company (Biotechnology) with a market capitalization of $2.2B. The Maz Rating grades it against the other companies in its sector.
Celldex Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $28.04, Celldex Therapeutics, Inc. trades at 19663.1x sales and 3.4x book value. Over the last twelve months it generated about $112007 of revenue and a net loss of $339M. It runs a gross margin of -662.5%, an operating margin of -298657.1% and a net margin of -275986.6%. It shows return on equity of -52.7%, return on invested capital of -50.5% and a free cash flow yield of -11.8%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 10.97. Over the past 52 weeks the share price ranged from $22.33 to $45.14, with a beta of 0.90.
Celldex Therapeutics, Inc. does not currently pay a dividend.
20 Wall Street analyst ratings cover the stock: 16 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. Their pipeline features therapeutic candidates aimed at both inflammatory conditions and various forms of cancer. Among their key clinical programs: CDX-0159 is a Phase I monoclonal antibody designed to bind to and inhibit the activity of the KIT receptor tyrosine kinase. CDX-1140 is a human agonist monoclonal antibody that targets CD40, a critical immune response activator found on immune cells such as dendritic cells, macrophages, and B cells, as well as on several cancer cell types. CDX-527 is a bispecific antibody that integrates Celldex's proprietary anti-PD-L1 and CD27 human antibodies. Its mechanism involves combining CD27 costimulation with blockade of the PD-L1/PD-1 pathway to prime and activate anti-tumor T-cell responses. The company has established several research collaborations and licensing agreements, including partnerships with the University of Southampton for developing human antibodies targeting CD27, Amgen Inc. for exclusive rights to CDX-301 and CD40 ligand, and Yale University. Incorporated in 1983, Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Celldex Therapeutics, Inc. (CLDX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 24.8% / 30% · Interest income / Revenue 669400000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 24.8% / 33% · Receivables / Mkt Cap (36m) 0.01% / 49% · Interest income / Revenue 669400000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 24.8% / 33.33% · Receivables / Mkt Cap (24m) 0.01% / 33.33% · Interest income / Revenue 669400000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.02% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 90.0% / 33.33% · Receivables / Avg Assets (4Q) 0.11% / 33.33% · Interest income / Revenue 669400000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 90.1% / 33.33% · (Cash+Recv) / Total Assets 90.2% / 33.33% · Interest income / Revenue 669400000.0% / 5% | Fail |
No. As of September 2026, Celldex Therapeutics, Inc. (CLDX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Celldex Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 669400000.0% of each dividend: Celldex Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.